Prostate Cancer
Conditions
Keywords
stage I prostate cancer, stage IIB prostate cancer, stage IIA prostate cancer, stage III prostate cancer
Brief summary
RATIONALE: Conformal radiation therapy uses a 3-dimensional (3-D) image of the tumor to help focus thin beams of radiation directly on the tumor. Giving conformal external-beam radiation therapy in higher doses over a shorter period of time may kill more tumor cells and have fewer side effects. Androgens can cause the growth of prostate cancer cells. Hormone therapy, such as leuprolide acetate, may lessen the amount of androgens made by the body. It is not yet known whether radiation therapy is more effective when given together with or without hormone therapy in treating patients with prostate cancer who have undergone surgery. PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with hormone therapy in treating patients who have undergone surgery for stage I, stage II, or stage III prostate cancer.
Detailed description
OBJECTIVES: * To investigate the potential benefit of post-operative radiotherapy with vs without a combined and adjuvant treatment consisting of short-term androgen suppression for improving the biochemical progression-free survival of patients who have undergone radical prostatectomy for stage I-III prostate cancer. OUTLINE: This is a multicenter study. Patients are stratified according to institution, pathological stage (pT2R1 vs pT3R0 vs pT3R1), Gleason sum (≤ 3+4 vs ≥ 4+3), and WHO performance status (0 vs 1). Within 3 months after radical surgery, patients are randomized to 1 of 2 treatment arms. * Arm I: Patients undergo post-operative conformal external beam irradiation for 6.5 weeks. * Arm II: Beginning between days -5 to -3, patients receive an antiandrogen for 2-4 weeks. Beginning on day 0, patients receive leuprolide acetate subcutaneously once (6-month depot) and undergo conformal external beam irradiation 5 times weekly for 6.5 weeks. Patients undergo quality of life assessments periodically. After completion of study treatment, patients are followed up every 6 months for 5 years and then yearly thereafter.
Interventions
Given systemically
DRUGleuprolide acetate
Given subcutaneously
RADIATION3-dimensional conformal radiation therapy
Undergo radiotherapy
Sponsors
European Organisation for Research and Treatment of Cancer - EORTC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
No minimum to 80 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of prostate cancer * Clinical stage cT1-2-3a, N0, M0 disease pre-operatively * Pre-operative PSA ≤ 5 x upper limit of normal * Presenting the following conditions after radical prostatectomy: * Gleason sum 5-10 * Pathologic stage pT2R1 (positive surgical margins with at least a tumor trans-section \> 2 mm) or pT3a-b (irrespective of margin status) * Negative lymph node (LN) status (pN0) by LN sampling or LN dissection * Unknown pathological LN status is not allowed, except for disease classified as cT ≤ cT1c with baseline PSA ≤ 10 ng/mL, Gleason score \< 7, and ≥ 12 positive core biopsies \< 50% * Undetectable post-operative PSA within 3 months of surgery PATIENT CHARACTERISTICS: * WHO performance status 0-1 * WBC ≥ 3 x 10\^9/L * Hemoglobin ≥ 110 g/L * Platelet count ≥ 100 x 10\^9/L * No other malignancy except adequately treated basal cell carcinoma of the skin or other malignancy from which the patient has been disease free for at least 5 years * No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule PRIOR CONCURRENT THERAPY: * See Disease Characteristics * More than 5 years since prior chemotherapy * No prior pelvic irradiation * No prior bilateral orchiectomy * No prior hormonal treatment except neoadjuvant treatment lasting ≤ 3 months * No other concurrent anticancer agent or modality
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Biochemical progression-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical progression-free survival | — |
| Distant-metastases-free survival | — |
| Overall survival | — |
| Quality of life as assessed by QLQ-C30 and QLQ-PR25 at baseline and at 6 months, 1 year, 2 years, and 5 years after treatment | — |
| Acute and late toxicity according to NCI CTCAE version 3.0 | — |
Countries
France
Outcome results
None listed